Evidence Intelligence™
- EvidenceScore™
- 83
- Strong
- ImpactScore™
- 79
- Positive
- ConsistencyScore™
- 100
- consistent
Estudios de apoyo: Basado en 7 estudios
Add to Evidence TrackerResumen de Investigación
Analyzed using Evidence Intelligence™
Liraglutide improves glycaemic control in type 2 diabetes
Última actualización 12 de septiembre de 2026
Key finding
Mean changes in HbA1c from baseline to week 26 with liraglutide were -0.98%.
This study evaluated the effects of liraglutide on glycaemic control in patients with Type 2 diabetes inadequately managed with SGLT2 inhibitors, finding significant improvements in HbA1c levels.
Quick read
Study at a glance
The essential study design details in one scan.
EvidenceScore™
Moderate
Study type
RCTs
Follow-up
Medium-Term (3–12 mo)
Risk of bias
Some Concerns
Guarda investigacion, organiza estudios y vuelve a encontrar evidencia importante rapidamente.
Plain-language summary
What this paper says
A plain-language read of the study’s main message and where it applies.
Study focus
This study evaluated the effects of liraglutide on glycaemic control in patients with Type 2 diabetes inadequately managed with SGLT2 inhibitors, finding significant improvements in HbA1c levels.
Clinical relevance
These findings are significant as they suggest that liraglutide can be an effective addition to the treatment regimen for patients with Type 2 diabetes who are not achieving adequate glycaemic control with SGLT2 inhibitors alone. Improved glycaemic control can lead to better long-term health outcomes and reduce the risk of diabetes-related complications.
Keep in mind
The study's sample size and population may limit generalizability. Potential biases in self-reported adverse events. Short duration of the study may not capture long-term effects.
Published in
Referencia de la Revista
Publication details and source links for this paper.
Lawrence B, Lidia B, Udi F, et al. Liraglutide Improves Glycaemic Control in Patients with Type 2 Diabetes Insufficiently Controlled with SGLT2 Inhibitors. Diabetes, Obesity & Metabolism. 2020;22(6):929-937. doi:10.1111/dom.13978
Efectos Principales
Liraglutide reduced HbA1c by -0.98% compared to -0.30% with placebo (p=0.001).
51.8% of liraglutide-treated patients achieved HbA1c < 7.0%, versus 23.2% on placebo.
Mean body weight decreased by -2.81 kg in the liraglutide group compared to -1.99 kg in the placebo group.
Evidence network
How this study fits
Understand where this research contributes within the broader evidence network.
Evidence Context
This study contributes evidence to Liraglutide and Body weight, HbA1c, Proportion achieving HbA1c <7.0%, and 1 more.
This study contributes evidence to
Primary intervention
Liraglutide
Primary outcomes
- Body weight
- HbA1c
- Proportion achieving HbA1c <7.0%
Evidence topics
Primary intervention
Primary outcomes
Evidence relationships
Intervention and outcome relationships this study adds to the evidence network.
4
Evidence pairs
4
Relationships
4
Evidence topics
contributes_evidence
Editorial context
Why this study matters
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
Moderate contributionModerate confidenceNetwork score: 68
4
Related topics
4
Evidence pairs
1104
Related studies
High relevance in at least one topic
Why it is useful
- Contributes to 4 evidence relationships
- Includes primary outcome data
- Linked to 4 direct semantic evidence topics
Topic contributions
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Agrega evidencia relacionada a tu Evidence Tracker
Guarda estudios y paginas de evidencia, organiza tu Evidence Tracker y manten en un solo lugar la investigacion que te importa.
Evidencia principal
Relación de evidencia
GLP-1 Receptor Agonists and HbA1c
Evidencia relacionada
Relación de evidencia
GLP-1 Receptor Agonists and Body Weight
Guardar evidencia
Tema de evidencia
HbA1c Reduction
Guardar evidencia
Core evidence
Study findings
The primary outcomes reported in this study.
Evidence Intelligence™
- EvidenceScore™
- 84
- Strong
- ImpactScore™
- 82
- Positive
- ConsistencyScore™
- 100
- consistent
Estudios de apoyo: Basado en 7 estudios
Add to Evidence TrackerProportion achieving HbA1c <7.0%
Liraglutide → Proportion achieving HbA1c <7.0%
Liraglutide → Proportion achieving HbA1c <7.0%
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Estudios de apoyo: Basado en 1 estudio
Add to Evidence TrackerTreatment-emergent adverse events
Liraglutide → Treatment-emergent adverse events
Liraglutide → Treatment-emergent adverse events
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- unclear
- Not enough independent studies
Estudios de apoyo: Basado en 1 estudio
Add to Evidence TrackerEvidence Library
Build your evidence library
Save research, organize studies, and quickly find important evidence again.
La Evidencia Sugiere
- Liraglutide significantly improved HbA1c levels by -0.98%.
- 51.8% of liraglutide patients reached HbA1c < 7.0%.
- 66.3% of liraglutide patients reported treatment-emergent adverse events.
A quién se aplica
- Adults with Type 2 diabetes inadequately controlled on SGLT2 inhibitors.
- Patients seeking additional treatment options for glycaemic control.
Tener en Cuenta
- Results may not apply to all populations with Type 2 diabetes.
- Adverse events were more common in the liraglutide group.
- Long-term effects of liraglutide were not assessed in this study.
Entre Líneas
- The study's sample size and population may limit generalizability.
- Potential biases in self-reported adverse events.
- Short duration of the study may not capture long-term effects.
Evidence Library
Build your evidence library
Save research, organize studies, and quickly find important evidence again.
Connected Evidence
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on GLP-1 Receptor Agonists and HbA1c, GLP-1 Receptor Agonists and Body Weight.
Relaciones de evidencia relacionadas
Explore in Evidence ExplorerThis study contributes to the evidence on the following intervention-outcome relationships.
Medications
GLP-1 Receptor Agonists → HbA1c
Medications
Evidence Intelligence™
- EvidenceScore™
- 84
- Strong
- ImpactScore™
- 82
- Positive
- ConsistencyScore™
- 100
- consistent
Estudios de apoyo: Basado en 7 estudios
View evidenceMedications
GLP-1 Receptor Agonists → Body Weight
Medications
Evidence Intelligence™
- EvidenceScore™
- 83
- Strong
- ImpactScore™
- 79
- Positive
- ConsistencyScore™
- 100
- consistent
Estudios de apoyo: Basado en 7 estudios
View evidenceIncluido en estas colecciones de evidencia
Curated evidence collections and hubs this study is part of.
Body Weight Evidence Hub
All studies measuring Body Weight
7 studies
outcome_hubMeasures Body Weight as a key outcome.
GLP-1 Receptor Agonists Evidence Hub
All studies on GLP-1 Receptor Agonists
7 studies
intervention_hubContributes to GLP-1 Receptor Agonists evidence base.
HbA1c Evidence Hub
All studies measuring HbA1c
7 studies
outcome_hubMeasures HbA1c as a key outcome.
Explora más en Evidence Explorer
Jump to pre-filtered views in Evidence Explorer.
All studies on Liraglutide and HbA1c
Intervention: LiraglutideOutcome: HbA1c
7 results
All studies on Liraglutide and Body weight
Intervention: LiraglutideOutcome: Body weight
7 results
All studies on Liraglutide
Intervention: Liraglutide
7 results
All studies measuring HbA1c
Outcome: HbA1c
7 results
All studies measuring Body weight
Outcome: Body weight
7 results
Questions answered by this study
Generated from the study's connected evidence using Evidence Intelligence™.
Do GLP-1 Receptor Agonists lower HbA1c?
Strong Evidence
GLP-1 Receptor Agonists appear to lower HbA1c.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
- 1
HbA1c
EvidenceScore™ Strong | EvidenceScore™ 84.0 | moderate positive | ConsistencyScore™ Consistent | 1 study
- 2
Proportion achieving HbA1c <7.0%
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on 45 supporting studies with consistent results and a positive effect signal.
Do GLP-1 Receptor Agonists affect body weight?
Strong Evidence
GLP-1 Receptor Agonists may affect body weight.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
- 1
Body weight
EvidenceScore™ Strong | EvidenceScore™ 83.2 | moderate positive | ConsistencyScore™ Consistent | 1 study
Why this answer: This answer is based on 43 supporting studies with consistent results and a positive effect signal.
Does Liraglutide affect treatment-emergent adverse events?
Emerging Evidence
Current evidence does not show a clear effect of Liraglutide on treatment-emergent adverse events.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
Treatment-emergent adverse events
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
Next steps
Continue your research
Choose a next path through related evidence topics, Evidence Explorer views, and research summaries.
Evidence topics
Follow the topics this study contributes to.
Explore in Evidence Explorer
Open broader Evidence Explorer views for this relationship.
Related research
Read related research summaries.
Sin anuncios. Sin rastreo.
Centrada en la evidencia, no en la publicidad.
Segura y privada
Tus datos siempre están protegidos.
Siempre al día
Se agregan nuevos estudios todos los días.